Copyright Reports & Markets. All rights reserved.

Global Cancer Biological Therapy Market Insights, Forecast to 2025

Request for Sample of this report
Buy now
  • 1.1 Research Scope
  • 1.2 Market Segmentation
  • 1.3 Research Objectives
  • 1.4 Research Methodology
    • 1.4.1 Research Process
    • 1.4.2 Data Triangulation
    • 1.4.3 Research Approach
    • 1.4.4 Base Year
  • 1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
    • 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
    • 1.5.2 Covid-19 Impact: Commodity Prices Indices
    • 1.5.3 Covid-19 Impact: Global Major Government Policy
  • 1.6 The Covid-19 Impact on Cancer Biological Therapy Industry
  • 1.7 COVID-19 Impact: Cancer Biological Therapy Market Trends

    • 2 Global Cancer Biological Therapy Quarterly Market Size Analysis

    • 2.1 Cancer Biological Therapy Business Impact Assessment - COVID-19
      • 2.1.1 Global Cancer Biological Therapy Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
    • 2.2 Global Cancer Biological Therapy Quarterly Market Size 2020-2021
    • 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
      • 2.3.1 Drivers
      • 2.3.2 Restraints
      • 2.3.3 Opportunities
      • 2.3.4 Challenges

    3 Quarterly Competitive Assessment, 2020

    • 3.1 By Players, Global Cancer Biological Therapy Quarterly Market Size, 2019 VS 2020
    • 3.2 By Players, Cancer Biological Therapy Headquarters and Area Served
    • 3.3 Date of Key Players Enter into Cancer Biological Therapy Market
    • 3.4 Key Players Cancer Biological Therapy Product Offered
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Impact of Covid-19 on Cancer Biological Therapy Segments, By Type

    • 4.1 Introduction
      • 1.4.1 Monoclonal Antibodies
      • 1.4.2 Vaccines
      • 1.4.3 Cancer Growth Blockers
      • 1.4.4 Blood Cell Growth Factors
    • 4.2 By Type, Global Cancer Biological Therapy Market Size, 2019-2021

    5 Impact of Covid-19 on Cancer Biological Therapy Segments, By Application

    • 5.1 Overview
      • 5.5.1 Hospitals
      • 5.5.2 Diagnostic Laboratories
      • 5.5.3 Research & Academic Laboratories
      • 5.5.4 Pharmaceutical & Biotechnology Companies
    • 5.2 By Application, Global Cancer Biological Therapy Market Size, 2019-2021
      • 5.2.1 By Application, Global Cancer Biological Therapy Market Size by Application, 2019-2021

    6 Geographic Analysis

    • 6.1 Introduction
    • 6.2 North America
      • 6.2.1 Macroeconomic Indicators of US
      • 6.2.2 US
      • 6.2.3 Canada
    • 6.3 Europe
      • 6.3.1 Macroeconomic Indicators of Europe
      • 6.3.2 Germany
      • 6.3.3 France
      • 6.3.4 UK
      • 6.3.5 Italy
    • 6.4 Asia-Pacific
      • 6.4.1 Macroeconomic Indicators of Asia-Pacific
      • 6.4.2 China
      • 6.4.3 Japan
      • 6.4.4 South Korea
      • 6.4.5 India
      • 6.4.6 ASEAN
    • 6.5 Rest of World
      • 6.5.1 Latin America
      • 6.5.2 Middle East and Africa

    7 Company Profiles

    • 7.1 ELI Lilly
      • 7.1.1 ELI Lilly Business Overview
      • 7.1.2 ELI Lilly Cancer Biological Therapy Quarterly Revenue, 2020
      • 7.1.3 ELI Lilly Cancer Biological Therapy Product Introduction
      • 7.1.4 ELI Lilly Response to COVID-19 and Related Developments
    • 7.2 Sanofi
      • 7.2.1 Sanofi Business Overview
      • 7.2.2 Sanofi Cancer Biological Therapy Quarterly Revenue, 2020
      • 7.2.3 Sanofi Cancer Biological Therapy Product Introduction
      • 7.2.4 Sanofi Response to COVID-19 and Related Developments
    • 7.3 Merck
      • 7.3.1 Merck Business Overview
      • 7.3.2 Merck Cancer Biological Therapy Quarterly Revenue, 2020
      • 7.3.3 Merck Cancer Biological Therapy Product Introduction
      • 7.3.4 Merck Response to COVID-19 and Related Developments
    • 7.4 Bayer
      • 7.4.1 Bayer Business Overview
      • 7.4.2 Bayer Cancer Biological Therapy Quarterly Revenue, 2020
      • 7.4.3 Bayer Cancer Biological Therapy Product Introduction
      • 7.4.4 Bayer Response to COVID-19 and Related Developments
    • 7.5 Roche
      • 7.5.1 Roche Business Overview
      • 7.5.2 Roche Cancer Biological Therapy Quarterly Revenue, 2020
      • 7.5.3 Roche Cancer Biological Therapy Product Introduction
      • 7.5.4 Roche Response to COVID-19 and Related Developments
    • 7.6 Novartis International
      • 7.6.1 Novartis International Business Overview
      • 7.6.2 Novartis International Cancer Biological Therapy Quarterly Revenue, 2020
      • 7.6.3 Novartis International Cancer Biological Therapy Product Introduction
      • 7.6.4 Novartis International Response to COVID-19 and Related Developments
    • 7.7 Pfizer
      • 7.7.1 Pfizer Business Overview
      • 7.7.2 Pfizer Cancer Biological Therapy Quarterly Revenue, 2020
      • 7.7.3 Pfizer Cancer Biological Therapy Product Introduction
      • 7.7.4 Pfizer Response to COVID-19 and Related Developments
    • 7.8 Bristol-Myers Squibb
      • 7.8.1 Bristol-Myers Squibb Business Overview
      • 7.8.2 Bristol-Myers Squibb Cancer Biological Therapy Quarterly Revenue, 2020
      • 7.8.3 Bristol-Myers Squibb Cancer Biological Therapy Product Introduction
      • 7.8.4 Bristol-Myers Squibb Response to COVID-19 and Related Developments
    • 7.9 Seattle Genetics
      • 7.9.1 Seattle Genetics Business Overview
      • 7.9.2 Seattle Genetics Cancer Biological Therapy Quarterly Revenue, 2020
      • 7.9.3 Seattle Genetics Cancer Biological Therapy Product Introduction
      • 7.9.4 Seattle Genetics Response to COVID-19 and Related Developments
    • 7.10 Amgen
      • 7.10.1 Amgen Business Overview
      • 7.10.2 Amgen Cancer Biological Therapy Quarterly Revenue, 2020
      • 7.10.3 Amgen Cancer Biological Therapy Product Introduction
      • 7.10.4 Amgen Response to COVID-19 and Related Developments
    • 7.11 Takeda Pharmaceuticals
      • 7.11.1 Takeda Pharmaceuticals Business Overview
      • 7.11.2 Takeda Pharmaceuticals Cancer Biological Therapy Quarterly Revenue, 2020
      • 7.11.3 Takeda Pharmaceuticals Cancer Biological Therapy Product Introduction
      • 7.11.4 Takeda Pharmaceuticals Response to COVID-19 and Related Developments
    • 7.12 GlaxoSmithKline
      • 7.12.1 GlaxoSmithKline Business Overview
      • 7.12.2 GlaxoSmithKline Cancer Biological Therapy Quarterly Revenue, 2020
      • 7.12.3 GlaxoSmithKline Cancer Biological Therapy Product Introduction
      • 7.12.4 GlaxoSmithKline Response to COVID-19 and Related Developments
    • 7.13 Spectrum Pharmaceuticals
      • 7.13.1 Spectrum Pharmaceuticals Business Overview
      • 7.13.2 Spectrum Pharmaceuticals Cancer Biological Therapy Quarterly Revenue, 2020
      • 7.13.3 Spectrum Pharmaceuticals Cancer Biological Therapy Product Introduction
      • 7.13.4 Spectrum Pharmaceuticals Response to COVID-19 and Related Developments
    • 7.14 Celgene Corporation
      • 7.14.1 Celgene Corporation Business Overview
      • 7.14.2 Celgene Corporation Cancer Biological Therapy Quarterly Revenue, 2020
      • 7.14.3 Celgene Corporation Cancer Biological Therapy Product Introduction
      • 7.14.4 Celgene Corporation Response to COVID-19 and Related Developments
    • 7.15 AstraZeneca, Plc.
      • 7.15.1 AstraZeneca, Plc. Business Overview
      • 7.15.2 AstraZeneca, Plc. Cancer Biological Therapy Quarterly Revenue, 2020
      • 7.15.3 AstraZeneca, Plc. Cancer Biological Therapy Product Introduction
      • 7.15.4 AstraZeneca, Plc. Response to COVID-19 and Related Developments
    • 7.16 Otsuka
      • 7.16.1 Otsuka Business Overview
      • 7.16.2 Otsuka Cancer Biological Therapy Quarterly Revenue, 2020
      • 7.16.3 Otsuka Cancer Biological Therapy Product Introduction
      • 7.16.4 Otsuka Response to COVID-19 and Related Developments
    • 7.17 Eisai
      • 7.17.1 Eisai Business Overview
      • 7.17.2 Eisai Cancer Biological Therapy Quarterly Revenue, 2020
      • 7.17.3 Eisai Cancer Biological Therapy Product Introduction
      • 7.17.4 Eisai Response to COVID-19 and Related Developments
    • 7.18 Abbvie
      • 7.18.1 Abbvie Business Overview
      • 7.18.2 Abbvie Cancer Biological Therapy Quarterly Revenue, 2020
      • 7.18.3 Abbvie Cancer Biological Therapy Product Introduction
      • 7.18.4 Abbvie Response to COVID-19 and Related Developments
    • 7.19 Incyte
      • 7.19.1 Incyte Business Overview
      • 7.19.2 Incyte Cancer Biological Therapy Quarterly Revenue, 2020
      • 7.19.3 Incyte Cancer Biological Therapy Product Introduction
      • 7.19.4 Incyte Response to COVID-19 and Related Developments

    8 Key Findings

      9 Appendix

      • 9.1 About US

      This report covers market size and forecasts of Cancer Biological Therapy, including the following market information:
      Global Cancer Biological Therapy Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global Cancer Biological Therapy Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global Cancer Biological Therapy Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global Cancer Biological Therapy Market Size by Company, 2019- 2020 (quarterly data), (US$ Million)

      Key market players
      Major competitors identified in this market include ELI Lilly, Sanofi, Merck, Bayer, Roche, Novartis International, Pfizer, Bristol-Myers Squibb, Seattle Genetics, Amgen, Takeda Pharmaceuticals, GlaxoSmithKline, Spectrum Pharmaceuticals, Celgene Corporation, AstraZeneca, Plc., Otsuka, Eisai, Abbvie, Incyte, etc.

      Based on the Region:
      Asia-Pacific (China, Japan, South Korea, India and ASEAN)
      North America (US and Canada)
      Europe (Germany, France, UK and Italy)
      Rest of World (Latin America, Middle East & Africa)

      Based on the Type:
      Monoclonal Antibodies
      Vaccines
      Cancer Growth Blockers
      Blood Cell Growth Factors

      Based on the Application:
      Hospitals
      Diagnostic Laboratories
      Research & Academic Laboratories
      Pharmaceutical & Biotechnology Companies

      Buy now